CASE REPORT
Interventional Cardiology
doi: 10.25005/2074-0581-2025-27-4-1063-1071
TRANSCATHETER AORTIC VALVE REPLACEMENT FOR MANAGING AORTIC REGURGITATION FOLLOWING LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION: A CASE REPORT

D. SUIGENBAYEV, I. KERIMKULOV, A. KASYMBAYEV, ZH. SAGTAGANOV

NJSC "Shymkent Heart Center", Shymkent, Republic of Kazakhstan

This article presents a case report involving a successful transcatheter aortic valve replacement (TAVR) in a 60-year-old female patient who had severe aortic regurgitation that developed six years after left ventricular assist device (LVAD) implantation. Due to the high surgical risk, the decision was made to perform TAVR via a femoral route with the Myval™ transcatheter heart valve (Meril Life Sciences Pvt. Ltd., Vapi, Gujarat, India)

The procedure was uneventful, and significant clinical improvements were observed in the postoperative period. These improvements included a transition of heart failure functional class from NYHA Class IV to II, normalization of hemodynamics, and the absence of paravalvular leaks. This case underscores the efficacy and safety of TAVR as an alternative approach for patients at high surgical risk. It confirms the role of innovative minimally invasive techniques in treating complex cardiovascular disease. The procedure was conducted with the patient's informed consent regarding the processing of her personal data.

Keywords: Transcatheter aortic valve replacement (TAVR), aortic regurgitation, left ventricular assist device (LVAD), minimally invasive surgery, cardiovascular surgery, clinical case.

Download file:

References
  1. Zhang B, Guo S, Fu Z, Liu Z. Minimally invasive versus conventional continuousflow left ventricular assist device implantation for heart failure: A meta-analysis. Heart Fail Rev. 2022;27(4):1053-61. https://doi.org/10.1007/s10741-021- 10102-z
  2. Phan K, Haswell JM, Xu J, Assem Y, Mick SL, Kapadia SR, et al. Percutaneous transcatheter interventions for aortic insufficiency in continuous-flow left ventricular assist device patients: A systematic review and meta-analysis. ASAIO J. 2017;63(2):117-22. https://doi.org/10.1097/MAT.0000000000000447
  3. Smood B, Han JJ, Helmers M, Atluri P. Mitral and aortic valve surgery during left ventricular assist device implantation. J Thorac Cardiovasc Surg. 2022;164(3):970- 7. https://doi.org/10.1016/j.jtcvs.2021.01.144
  4. Acharya D, Kazui T, Al Rameni D, Acharya T, Betterton E, Juneman E, et al. Aortic valve disorders and left ventricular assist devices. Front Cardiovasc Med. 2023;10:1098348. https://doi.org/10.3389/fcvm.2023.1098348
  5. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561-632. https://doi.org/10.1093/eurheartj/ehab395
  6. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/ EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739-91. https://doi.org/10.1093/eurheartj/ehx391
  7. Vakil K, Kazmirczak F, Sathnur N, Adabag S, Cantillon DJ, Kiehl EL, et al. Implantable cardioverter-defibrillator use in patients with left ventricular assist devices: A systematic review and meta-analysis. JACC Heart Fail. 2016;4(10):772-9. https:// doi.org/10.1016/j.jchf.2016.05.003
  8. Clegg AJ, Scott DA, Loveman E, Colquitt J, Hutchinson J, Royle P, et al. The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: A systematic review and economic evaluation. Health Technol Assess. 2005;9(45):1-iv. https://doi.org/10.3310/hta9450
  9. Blumer V, Mendirichaga R, Hernandez GA, Zablah G, Chaparro SV. Sex-specific outcome disparities in patients receiving continuous-flow left ventricular assist devices: A systematic review and meta-analysis. ASAIO J. 2018;64(4):440-9. https://doi.org/10.1097/MAT.0000000000000695
  10. Agrawal S, Garg L, Nanda S, Sharma A, Bhatia N, Manda Y, et al. The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices – A meta-analysis. Int J Cardiol. 2016;222:379-84. https://doi.org/10.1016/j.ijcard.2016.07.257
  11. Kittipibul V, Rattanawong P, Kewcharoen J, Chongsathidkiet P, Vutthikraivit W, Kanjanahattakij N. Atrial fibrillation is not associated with thromboembolism in left ventricular assist device patients: A systematic review and meta-analysis. ASAIO J. 2019;65(5):456-64. https://doi.org/10.1097/MAT.0000000000000832
  12. Vriz O, Mushtaq A, Shaik A, El-Shaer A, Feras K, Eltayeb A, et al. Reciprocal interferences of the left ventricular assist device and the aortic valve competence. Front Cardiovasc Med. 2023;9:1094796. https://doi.org/10.3389/ fcvm.2022.1094796
  13. Saia F, Loforte A, Pacini D. Innovative transcatheter procedures for the treatment of heart failure. Cardiovasc Diagn Ther. 2021;11(1):292-300. https://doi. org/10.21037/cdt-20-335
  14. Chang HH, Chen PL, Chen YH, Leu HB, Kuo CC, Wu NY. Intraoperative ECMO assistance during TAVI for aortic insufficiency in an Asian patient with LVAD support. ESC Heart Fail. 2021;8(4):3418-21. https://doi.org/10.1002/ehf2.13426
  15. Sammartino AM, Bonfioli GB, Dondi F, Riccardi M, Bertagna F, Metra M, et al. Contemporary role of positron emission tomography (PET) in endocarditis: A narrative review. J Clin Med. 2024;13(14):4124. https://doi.org/10.3390/ jcm13144124
  16. Blasco-Turrión S, Crespo-Leiro MG, Donoso Trenado V, Chi Hion PL, Díaz Molina B, Roura G, et al. Structural heart transcatheter interventions in orthotopic cardiac transplant and left ventricular assist devices recipients: A nationwide study. Int J Cardiol. 2024;413:132340. https://doi.org/10.1016/j.ijcard.2024.132340
  17. Hinkov H, Lee CB, Pitts L, Lanmüller P, Klein C, Kukucka M, et al. Transcatheter management of pure native aortic valve regurgitation in patients with left ventricular assist device. Eur J Cardiothorac Surg. 2024;65(3):ezae028. https:// doi.org/10.1093/ejcts/ezae028
  18. de Sá Marchi MF, Verhemel S, Nuis RJ, Van Mieghem NM. Case report of increased left ventricular end-diastolic pressure with pulsatile left ventricular assist device. Eur Heart J Case Rep. 2024;8(6):ytae291. https://doi.org/10.1093/ ehjcr/ytae291
  19. Hamieh M, Nassereddine Z, Moussa M, Al Ali F, Dbouk M, Saab M. Transcatheter aortic valve implantation for aortic regurgitation in HeartMate II supported patient using Myval THV: A case report. Oxf Med Case Rep. 2023;2023(10):omad086. https://doi.org/10.1093/omcr/omad086
  20. Shalabi A, Kachel E, Kassif Y, Faqeeh M, Sergey P, Sternik L, et al. Unusual complications following left ventricular assisted device implantation: Case series. J Cardiothorac Surg. 2021;16(1):70. https://doi.org/10.1186/s13019-021-01445- 7
  21. Wiechmann RJ, Lee LY, Yu Y, Prillinger JB, Gutfinger D, Blakeman B. Ten-year outcomes of surgical aortic valve replacement with a contemporary supraannular porcine valve in a Medicare population. JTCVS Open. 2022;12:84-102. https://doi.org/10.1016/j.xjon.2022.08.002
  22. Stein C, Maroncelli A, Bose R, Roberts SM. Transcatheter aortic valve embolization in a patient with a left ventricular assist device. CASE (Phila). 2024;8(2):46-9. https://doi.org/10.1016/j.case.2023.11.010
  23. Ali J, Catarino P, Abu-Omar Y. Transcatheter aortic valve implantation in patients with a left ventricular assist device: A word of caution. Eur J Cardiothorac Surg. 2020;58(6):1309-10. https://doi.org/10.1093/ejcts/ezaa237
  24. Schmitz KT, Inglis SS, Villavicencio MA, daSilva-deAbreu A. HeartMate 3 upgrade and aortic root replacement for severe aortic insufficiency and ventricular fibrillation. JHLT Open. 2025;8:100205. https://doi.org/10.1016/j. jhlto.2024.100205
  25. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, et al. Twoyear outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366(18):1686-95. https://doi.org/10.1056/NEJMoa1200384
  26. Zoghbi WA. New recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound. Methodist Debakey Cardiovasc J. 2010;6(1):20-6. https://doi.org/10.14797/mdcj-6-1-20
  27. Yoon SH, Kim WK, Dhoble A, Milhorini Pio S, Babaliaros V, Jilaihawi H, et al. Bicuspid aortic valve morphology and outcomes after transcatheter aortic valve replacement. J Am Coll Cardiol. 2020;76(9):1018-30. https://doi.org/10.1016/j. jacc.2020.07.005
  28. Gondi KT, Tam MC, Chetcuti SJ, Pagani FD, Grossman PM, Deeb GM, et al. Transcatheter aortic valve replacement for left ventricular assist device-related aortic regurgitation: The Michigan Medicine experience. J Soc Cardiovasc Angiogr Interv. 2022;2(1):100530. https://doi.org/10.1016/j.jscai.2022.100530
  29. Zhang X, Puehler T, Frank D, Sathananthan J, Sellers S, Meier D, et al. TAVR for all? The surgical perspective. J Cardiovasc Dev Dis. 2022;9(7):223. https://doi. org/10.3390/jcdd9070223
  30. Larusdottir KJ, Gudmundsson H, Johnsen A, Sigurdsson MI, Gudbjartsson T, Gudmundsdottir IJ. [Article in Icelandic]. Laeknabladid. 2021;107(3):123–129. https://doi.org/10.17992/lbl.2021.03.625
  31. Sammour Y, Krishnaswamy A, Kumar A, Puri R, Tarakji KG, Bazarbashi N, et al. Incidence, predictors, and implications of permanent pacemaker requirement after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2021;14(2):115-34. https://doi.org/10.1016/j.jcin.2020.09.063
  32. Estep JD, Starling RC, Horstmanshof DA, Milano CA, Selzman CH, Shah KB, et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study. J Am Coll Cardiol. 2015;66(16):1747-61. https://doi. org/10.1016/j.jacc.2015.07.075
  33. Sanchez-Luna JP, Martín P, Dager AE, Charry PD, Beltrán JR, Sánchez-Recalde Á, et al. Clinical outcomes of TAVI with the Myval balloon-expandable valve for noncalcified aortic regurgitation. EuroIntervention. 2023;19(7):580-8. https://doi. org/10.4244/EIJ-D-23-00344
  34. Kilic A, Acker MA, Atluri P. Dealing with surgical left ventricular assist device complications. J Thorac Dis. 2015;7(12):2158-64. https://doi.org/10.3978/j. issn.2072-1439.2015.10.64
  35. Giuliani C, Zanuttini A, Hecht S, Ternacle J, Pibarot P. Prosthesis-patient mismatch: Current state of evidence. Curr Cardiol Rep. 2025;27(1):49. https:// doi.org/10.1007/s11886-025-02212-z
  36. Legeza P, Britz GW, Loh T, Lumsden A. Current utilization and future directions of robotic-assisted endovascular surgery. Expert Rev Med Devices. 2020;17(9):919- 27. https://doi.org/10.1080/17434440.2020.1814742
  37. Maltais S, Davis ME, Haglund N. Minimally invasive and alternative approaches for long-term LVAD placement: The Vanderbilt strategy. Ann Cardiothorac Surg. 2014;3(6):563-9. https://doi.org/10.3978/j.issn.2225-319X.2014.10.02
  38. Langer NB, Nazif TM. TAVI for noncalcified aortic insufficiency in high-risk patients. Eur Heart J. 2020;41(3):234-41.
  39. Ullah W, DiMeglio M, Sana MK, Muhammadzai HZU, Kochar K, Zahid S, et al. Outcomes after transcatheter aortic valve implantation in patients excluded from clinical trials. JACC Adv. 2023;2(2):100271. https://doi.org/10.1016/j. jacadv.2023.100271
  40. Kilic T, Coskun S, Mirzamidinov D, Yilmaz I, Yavuz S, Sahin T. Myval transcatheter heart valve: The future of transcatheter valve replacement and significance in current timeline. J Clin Med. 2024;13(22):6857. https://doi.org/10.3390/ jcm13226857
  41. Yamamoto H, Nakayama T, Ishii N, Nakamura Y. Minimally invasive surgical versus transcatheter aortic valve replacement: A retrospective observational single-center study in Japan. Innovations (Phila). 2023;18(6):547-56. https://doi. org/10.1177/15569845231205587

Authors' information:

Suigenbayev Darkhan,
Chairman of the Board, NJSC "Shymkent Heart Center"
Scopus ID: 56641807400
ORCID ID: 0009-0005-5942-8102
E-mail: darhanarman5@gmail.com

Kerimkulov Issabek,
Head of the Angiography Department, NJSC "Shymkent Heart Center"
ORCID ID: 0009-0006-7905-0415
E-mail: Dr.isabek01@gmail.com

Kasymbayev Adkham,
Interventional Cardiologist, NJSC "Shymkent Heart Center"
ORCID ID: 0009-0005-5016-9466
E-mail: adham.mua@gmail.com

Sagtaganov Zhaxybek,
MD, PhD, Director of the Department of Science, Education, and Strategy, NJSC "Shymkent Heart Center"
Scopus ID: 58038186100
ORCID ID: 0000-0002-6459-398X
E-mail: sagtaganovzaksybek@gmail.com

Information about support in the form of grants, equipment, medications

The authors did not receive financial support from manufacturers of medicines and medical equipment

Conflicts of interest: No conflict

Address for correspondence:

Sagtaganov Zhaxybek
MD, PhD, Director of the Department of Science, Education, and Strategy, NJSC "Shymkent Heart Center"

160021, Republic of Kazakhstan, Shymkent, A. Baitursynov str., 79a

Tel.: +7 (702) 9748222

E-mail: sagtaganovzaksybek@gmail.com


This work is licensed under a Creative Commons Attribution 4.0 International License.

Materials on the topic:
  1. THE LONG-TERM EFFICACY OF DIFFERENT ENDOVASCULAR TREATMENTS FOR CORONARY ARTERY CALCIFICATION FOLLOWED BY STENTING
  2. COMPARATIVE ANALYSIS OF ENDOVASCULAR TREATMENT METHODS FOR CORONARY ARTERY CALCIFICATION DURING STENTING: INTRAOPERATIVE STUDY RESULTS
  3. CORONARY ARTERY CALCIFICATION: PATHOGENESIS AND METHODS OF MYOCARDIAL REVASCULARIZATION
  4. STRATIFIED APPROACH TO PREVENTION OF NO-REFLOW PHENOMENON DURING ENDOVASCULAR TREATMENT OF PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION

◄ Back to the list